simplyStocks
Explore all companies →
ILMN

Illumina, Inc.

ILMN · NASDAQHealthcare · Life-Science Tools
The economic chain
Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
Inputs &supplyReagents, enzymes, flow c…SequencingsystemsInstruments + consumablesData &informaticsDRAGEN, BaseSpace, cloudLabs &applicationsClinical, research, pharmaResearchers &patientsDiscovery & diagnosisRGTReagent & enzyme suppliersOPTFlow-cell & optics vendorsILMNIlluminaPACBPacific BiosciencesTMOThermo Fisher (Ion Torrent)ONOxford NanoporeM/CGMGI / Complete GenomicsD&BDRAGEN & BaseSpaceRESResearch institutionsLABClinical & diagnostic labsPHAPharma & biotechSCIScientistsPATPatients
Company details
Market cap
~$16B
P/E (adj., fwd)
~25×
Div yield
0%
Gross margin
65%
R&D / revenue
~25%
Rev. growth
-3%
Revenue (FY24)
$4.4B
Consumables mix
72%
In plain English
Illumina makes the machines that read DNA. It dominates next-generation sequencing (NGS) — its NovaSeq, NextSeq and MiSeq systems sit in most of the world's genomics labs — and, like a razor-and-blades business, ~72% of its ~$4.4B revenue is the consumables (flow cells and reagents) those installed sequencers burn through on every run.
In simple terms
What Illumina, Inc. really sells
Illumina makes the machines that read DNA. It dominates next-generation sequencing (NGS) — its NovaSeq, NextSeq and MiSeq systems sit in most of the world's genomics labs — and, like a razor-and-blades business, ~72% of its ~$4.4B revenue is the consumables (flow cells and reagents) those installed sequencers burn through on every run.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.
Risk read
Elevated
SteadierMore speculative
Why this rating?